Dainippon Sumitomo Transfers Growth Hormone Business To JCR
This article was originally published in PharmAsia News
Executive Summary
From July, Dainippon Sumitomo Pharma will exit a joint-promotion deal with Japan Chemical Research on Growject, a recombinant human growth hormone injection